Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:July 24, 2018
End Date:September 19, 2020
Contact:Patients Contact: Patient Advocacy
Email:patientadvocacy@ultragenyx.com
Phone:1-415-483-8800

Use our guide to learn which trials are right for you!

A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6- Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)

The primary objective of the study is to determine the safety of single doses of DTX401,
including the incidence of dose-limiting toxicities (DLTs) at each dose level.


Inclusion Criteria:

- Males and females ≥18 years of age

- Documented GSDIa with confirmation by molecular testing

- Documented history of ≥1 hypoglycemic event with blood glucose <60 mg/dL (<3.33
mmol/L)

- Patient's GSDIa disease is stable as evidenced by no hospitalization for severe
hypoglycemia during the 4-week period preceding the screening visit

Exclusion Criteria:

- Anti-AAV8 neutralizing antibody titer ≥1:5

- Screening or Baseline (Day 0) blood glucose level <60 mg/dL (<3.33 mmol/L)

- Liver transplant, including hepatocyte cell therapy/transplant

- Presence of liver adenoma >5 cm in size

- Presence of liver adenoma >3 cm and ≤5 cm in size that has a documented annual growth
rate of ≥0.5 cm per year

- Significant hepatic inflammation or cirrhosis as evidenced by imaging or any of the
following laboratory abnormalities: alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) > upper limit of normal (ULN), total bilirubin >1.5 × ULN,
alkaline phosphatase >2.5 × ULN

Note additional inclusion/exclusion criteria may apply, per protocol.
We found this trial at
4
sites
1150 East Medical Center Drive
Ann Arbor, Michigan 48109
Principal Investigator: Ayesha Ahmad, MD
Phone: 734-615-1471
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Farmington, Connecticut 06032
Principal Investigator: David A. Weinstein, MD, MMSC
Phone: 860-837-7856
?
mi
from
Farmington, CT
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Santiago De Compostela, A Coruna 15706
?
mi
from
Santiago De Compostela,
Click here to add this to my saved trials